Drug Profile
Research programme: hepatitis C virus NS3 protease inhibitors - Bristol-Myers Squibb
Alternative Names: BMS-605339Latest Information Update: 02 Sep 2010
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Peptide fragments; Small molecules; Sulfonamides
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 26 Aug 2010 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 20 Aug 2009 Early research in Hepatitis C in USA (unspecified route)